Abstracts tagged "Cohort Study"

Abstract Number: 2025 • ACR Convergence 2022
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Brandon Law¹, Margaret Beach², Eileen Pelayo², Ilias Alevizos², Zohreh Khavandgar², Blake Warner² and Alan Baer¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 1014 • ACR Convergence 2022
Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Serge Steinfeld³, Adrien NZEUSSEU TOUKAP⁴, Dirk Elewaut⁵, Rik Lories⁶, Filip Van den bosch⁷ and Kurt de Vlam⁸, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Clinique Saint-Jean, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁸University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA). This study, using clinical and radiographical definitions of axial involvement, investigated the…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1811 • ACR Convergence 2022
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Emily Fan¹ and Megan Krause², ¹University of Kansas School of Medicine, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Identifying patients with gout who would benefit from urate lowering therapies (ULT) is of utmost importance to help limit both pain and functional pain.…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
Abstract Number: 0340 • ACR Convergence 2022
Birth Order Is a Risk Factor for Systemic Lupus Erythematosus
Nicole Shammas¹, Priya Ramani², Christopher Aston³, Ana Quintero-Del-Rio⁴, Judith James⁵, John Harley⁶, Isaac Harley⁷ and Hal Scofield⁵, ¹University of Colorado School of Medicine, Aurora, CO, ²Tampa Rheumatology, Tampa, FL, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴OU Children's Hospital, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Birth order effects have been described in several immune and non-immune disease states. While some studies have found an increased risk of developing autoimmune…
Abstract Number: 1026 • ACR Convergence 2022
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
Paras Karmacharya¹, Courtney Stull², Alisa Stephens-Shields³, M. Elaine Husni⁴, Jose Scher⁵, Ethan Craig⁶, Robert Fitzsimmons³, Soumya Reddy⁷, Marina Magrey⁸, Alexis Ogdie⁹ and Jessica Walsh¹⁰, ¹Vanderbilt University, Nashville, TN, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, ⁴Cleveland Clinic, Cleveland, OH, ⁵New York University School of Medicine, New York, NY, ⁶University of Pennsylvania, Wallingford, PA, ⁷NYU School of Medicine, New York, NY, ⁸Case Western Reserve University, University Hospitals, Richfield, OH, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah, Salt Lake City, UT
Background/Purpose: Despite significant heterogeneity in psoriatic arthritis (PsA), randomized controlled trials (RCTs) generally enroll a homogenous subgroup of PsA patients (polyarticular similar to rheumatoid arthritis).…
Abstract Number: 1371 • ACR Convergence 2022
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Amita Aggarwal¹, Liza Rajasekhar², Parasar Ghosh³, Ashish J Mathew⁴, Chengappa Kavadichanda⁵, Vineetha Shobha⁶, Ranjan Gupta⁷, Saumya Ranjan Tripathy⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶St. John’s Medical College Hospital, Bangalore, India, ⁷All India Institute of Medical Sciences, New Delhi, India, ⁸SCB medical college, Cuttack, India, ⁹PGIMER Chandigarh, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Christopher Bell¹, Bernie Rubin², Karen Worley³, Guillaume Germain⁴, François Laliberté⁴, Sean D. MacKnight⁴, Ana Urosevic⁴ and Mei Sheng Duh⁵, ¹GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ³GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, ⁴Groupe d’analyse, Montréal, QC, Canada, ⁵Analysis Group Inc, Boston, MA
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…
Abstract Number: 1395 • ACR Convergence 2022
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao-Fan Fang¹ and Lai-Chu See², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan
Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
Abstract Number: 1845 • ACR Convergence 2022
Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study
Pamela Doti¹, Ana Luisa Cunha², Armin Quispe Cornejo³, Ángela Nieto González¹, Andre Matos¹, Pedro Guevara Hernández¹, Pedro Castro Rebollo¹ and Gerard Espinosa Garriga¹, ¹Hospital Clínic, Barcelona, Spain, ²Hospital Senhora da Oliveira, Guimarães, Porto, Portugal, ³Erasme Hospital, Brussels, Belgium
Background/Purpose: To describe the clinical characteristics of a 20-year cohort of patients with systemic autoimmune diseases (SAD) admitted to a medical intensive care unit (ICU)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].